Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06026319 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Jan 1, 2027 → Aug 1, 2027
See other at-risk trials from Marcela V. Maus, M.D.,Ph.D.

Record History

  1. Primary completion pushed from Jan 1, 2027 to Aug 1, 2027 Completion pushed from Jan 1, 2028 to Aug 1, 2028 · Eligibility criteria expanded, about 49 words · Study description expanded, about 2 words Show 3 more changesShow less
    • Completion pushed from Jan 1, 2028 to Aug 1, 2028
    • Eligibility criteria expanded, about 49 words
    • Study description expanded, about 2 words
  2. Re-verified, no change to tracked fieldsv6
  3. Eligibility criteria expanded, about 13 words Site contact updatedv5 Show 1 more changeShow less
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Oct 2025 to Jan 1, 2027 Completion date: Oct 2027 to Jan 1, 2028v4 Show 1 more changeShow less
    • Completion date: Oct 2027 to Jan 1, 2028
  5. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Feb 2024 to Oct 26, 2023 · Site details revisedv3 Show 2 more changesShow less
    • Start date changed from estimate of Feb 2024 to Oct 26, 2023
    • Site details revised
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Marcela V. Maus, M.D.,Ph.D.
6 trials monitored
See 3 trials at risk
Non-Hodgkin Lymphoma
1,517 trials monitored
See 84 trials at risk
DLBCL
650 trials monitored
See 38 trials at risk
Follicular Lymphoma
313 trials monitored
See 26 trials at risk
and 1 more disease
This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Trial Details
NCT Number NCT06026319
Lead Sponsor Marcela V. Maus, M.D.,Ph.D.
Conditions Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High-grade B-cell Lymphoma +2 more
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov